Photo Credit: Getty Images
Researchers at the University of Cambridge have developed what they describe as a fundamentally new kind of vaccine, using artificial intelligence to design its core component entirely from scratch, marking the first time an AI-engineered antigen has been tested in human volunteers.
The vaccine was built to target the entire coronavirus family, covering all known Covid variants as well as related viruses currently circulating in animals that carry the potential to spark the next global pandemic. The team is already applying the same technology to develop separate vaccines targeting influenza and Ebola, signalling ambitions that stretch well beyond coronaviruses.
The central challenge the researchers set out to solve is one that has long plagued vaccine science, the ability of viruses to mutate rapidly, rendering existing vaccines outdated and forcing annual reformulations for diseases like Covid and seasonal flu. Professor Jonathan Heeney, who led the Cambridge team, described the current state of vaccine development as perpetually reactive, and said the goal of this new approach was to get so far ahead of viral evolution that future outbreaks and pandemics could be neutralised before they take hold.
To build the vaccine, the team fed genetic sequences from a wide range of coronaviruses, collected through global surveillance programmes monitoring potential viral threats, into an AI system. The AI then designed a so-called super-antigen, a vaccine component engineered to train the immune system to recognise and fight an entire family of viruses, including mutated strains and those not yet known to infect humans.
Initial trials involving 39 participants focused on safety assessment, with results published in the Journal of Infection describing the immune response generated as modest but encouraging. A second, larger study involving around 200 people is now underway to more thoroughly measure the vaccine's effectiveness at stimulating immunity.
Independent experts, including Professor Andy Pollard of the Oxford Vaccine Group, called the early animal research compelling and described AI's broader role in vaccine development as a potential game changer, one capable of dramatically accelerating the path from discovery to deployment and, ultimately, saving lives.
